Key Takeaways
- Tirzepatide vs semaglutide comes down to dual agonist vs single agonist: tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone
- The only head-to-head trial (SURPASS-2) found tirzepatide superior to semaglutide for both blood sugar control and weight loss
- In separate obesity trials, tirzepatide 15mg achieved 20.9% weight loss at 72 weeks vs semaglutide 2.4mg's 14.9% at 68 weeks
- Semaglutide has proven cardiovascular benefit (SELECT trial: 20% MACE reduction); tirzepatide's CV outcome data is still pending
- Both are FDA-approved and available as brand-name injectables and compounded formulations
Plan Your Dosing Schedule
Use our free calculators to visualize drug levels, plan titration, and track your progress.
Tirzepatide vs semaglutide is one of the most common comparisons in the GLP-1 space, and for good reason. These two peptides represent the current gold standard for weight management and blood sugar control, but they work through different mechanisms and produce meaningfully different results in clinical trials.
Tirzepatide (sold as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Semaglutide (sold as Ozempic and Wegovy) is a GLP-1 receptor agonist made by Novo Nordisk. Both are available as weekly subcutaneous injections, and both are widely used as compounded formulations.
Below: mechanism of action, clinical trial results, dosing protocols, side effects, cost, and cardiovascular data.
Tirzepatide vs Semaglutide: Quick Comparison
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual Agonist (GLP-1 + GIP) | Single Agonist (GLP-1 only) |
| Brand Names | Mounjaro, Zepbound | Ozempic, Wegovy, Rybelsus |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Half-Life | ~5 days | ~7 days |
| Dosing Range | 2.5mg → 15mg weekly | 0.25mg → 2.4mg weekly (7.2mg max) |
| Max Weight Loss (Trials) | -20.9% at 72 weeks | -14.9% at 68 weeks |
| FDA Approval (Diabetes) | Mounjaro (May 2022) | Ozempic (Dec 2017) |
| FDA Approval (Obesity) | Zepbound (Nov 2023) | Wegovy (Jun 2021) |
| CV Outcome Data | Pending (SURPASS-CVOT) | Proven (SELECT: 20% MACE ↓) |
| Oral Form Available | No | Yes (Rybelsus) |
| Steady State | ~4 weeks | ~4-5 weeks |
Mechanism of Action: How Tirzepatide and Semaglutide Work
The fundamental difference between tirzepatide and semaglutide is receptor targeting. Both peptides mimic natural gut hormones that regulate appetite and blood sugar, but tirzepatide hits two targets where semaglutide hits one.
Semaglutide: GLP-1 Receptor Agonist
Semaglutide activates a single receptor type:
- GLP-1 (Glucagon-like peptide-1): Slows gastric emptying, suppresses appetite at the hypothalamic level, and stimulates insulin secretion in a glucose-dependent manner
Semaglutide has been studied extensively since 2017 and has the longest track record of any injectable GLP-1 agonist on the market. Its longer half-life (~7 days) means slightly more stable blood levels between weekly injections. For detailed protocols, see our semaglutide dosing guide.
Tirzepatide: Dual GIP/GLP-1 Receptor Agonist
Tirzepatide activates two receptor types simultaneously:
- GLP-1: Same appetite suppression and insulin-stimulating benefits as semaglutide
- GIP (Glucose-dependent insulinotropic polypeptide): Improves insulin sensitivity, influences fat metabolism, and may change how the body responds to nutrient intake
GIP receptor activation is what sets tirzepatide apart. GIP was historically underestimated, but it turns out to be important for energy balance and fat tissue regulation. This dual action likely explains why tirzepatide beats semaglutide on weight loss in every trial. For comparisons with next-generation triple agonists, see our retatrutide vs semaglutide analysis. See our tirzepatide dosing guide for more on protocols.
Why GIP Matters
GIP receptor agonism was once considered counterproductive for weight loss. Early research suggested GIP promoted fat storage. But at pharmacological doses, GIP agonists appear to do the opposite: they improve insulin sensitivity and amplify the weight loss from GLP-1. That's likely why tirzepatide consistently outperforms semaglutide in clinical data.
Tirzepatide vs Semaglutide Dosing Schedules
Both medications use weekly subcutaneous injections with gradual dose titration. The escalation schedules differ significantly in their dose ranges and number of steps. For printable references, see the tirzepatide dosage chart and semaglutide dosage chart.
Tirzepatide Dosing (Mounjaro/Zepbound)
| Phase | Dose | Duration |
|---|---|---|
| Starting | 2.5mg weekly | 4 weeks |
| Escalation 1 | 5mg weekly | 4 weeks |
| Escalation 2 | 7.5mg weekly | 4 weeks |
| Escalation 3 | 10mg weekly | 4 weeks |
| Escalation 4 | 12.5mg weekly | 4 weeks |
| Maximum | 15mg weekly | Maintenance |
Semaglutide Dosing (Wegovy Protocol)
| Phase | Dose | Duration |
|---|---|---|
| Starting | 0.25mg weekly | 4 weeks |
| Escalation 1 | 0.5mg weekly | 4 weeks |
| Escalation 2 | 1.0mg weekly | 4 weeks |
| Escalation 3 | 1.7mg weekly | 4 weeks |
| Maintenance | 2.4mg weekly | Recommended; 7.2mg maximum |
Pharmacokinetic Note
Semaglutide has a longer half-life (~7 days) compared to tirzepatide (~5 days). This means semaglutide reaches steady state slightly later but maintains more consistent blood levels between doses. Tirzepatide users may notice slightly more fluctuation between injection days. Use our tirzepatide calculator or semaglutide calculator to visualize how drug levels behave across your specific schedule.
Clinical Trial Results: Weight Loss Compared
Both tirzepatide and semaglutide have extensive clinical trial programs. Critically, there is one head-to-head study (SURPASS-2) that directly compared the two, plus large independent obesity trials for each.
SURPASS-2: The Only Head-to-Head Trial
The SURPASS-2 trial (NEJM, 2021) is the most important study in this comparison because it directly tested tirzepatide against semaglutide in 1,879 patients with type 2 diabetes over 40 weeks.
| Metric | Tirz 5mg | Tirz 10mg | Tirz 15mg | Sema 1mg |
|---|---|---|---|---|
| HbA1c Reduction | -2.01% | -2.24% | -2.30% | -1.86% |
| Extra Weight Loss vs Sema | -1.9 kg | -3.6 kg | -5.5 kg | - |
| Nausea | 17% | 20% | 22% | 18% |
| Diarrhea | 13% | 16% | 14% | 12% |
Important Limitation
SURPASS-2 compared tirzepatide against semaglutide 1mg (the Ozempic dose for diabetes), not the higher 2.4mg dose used for weight loss (Wegovy). At the time of the trial, the 2.4mg dose was not yet widely available. This means the comparison slightly favors tirzepatide, though all three tirzepatide doses still showed statistically significant advantages.
SURMOUNT-1: Tirzepatide for Obesity
The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks:
| Dose Group | Mean Weight Loss | ≥5% Loss | ≥20% Loss |
|---|---|---|---|
| 5mg | -15.0% | 85% | - |
| 10mg | -19.5% | 89% | 50% |
| 15mg | -20.9% | 91% | 57% |
| Placebo | -3.1% | 35% | 3% |
STEP 1: Semaglutide for Obesity
The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks:
| Group | Mean Weight Loss | ≥5% Loss | ≥15% Loss |
|---|---|---|---|
| Semaglutide 2.4mg | -14.9% | 86.4% | 50.5% |
| Placebo | -2.4% | 31.5% | 4.9% |
Cross-Trial Summary
Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes. Even tirzepatide's lowest dose (5mg, -15.0%) matched semaglutide's 2.4mg result (-14.9%). A 2025 real-world study from Bangladesh confirmed these patterns in clinical practice.
Tirzepatide vs Semaglutide Side Effects
Both medications share a similar side effect profile dominated by gastrointestinal symptoms. The SURPASS-2 head-to-head trial provides the cleanest comparison, since both groups were studied under identical conditions.
Side-by-Side: SURPASS-2 Data
| Side Effect | Tirzepatide (5-15mg) | Semaglutide (1mg) |
|---|---|---|
| Nausea | 17–22% | 18% |
| Diarrhea | 13–16% | 12% |
| Vomiting | 6–10% | 8% |
| Decreased Appetite | 5–10% | 9% |
| Serious Adverse Events | 5–7% | 3% |
In practical terms, the GI side effects are comparable. Both medications are most problematic during dose escalation phases and tend to improve as the body adapts. The slightly higher serious adverse event rate with tirzepatide in SURPASS-2 has not raised safety concerns in subsequent, larger trials.
Managing Side Effects
The same strategies apply to both compounds:
- Titrate slowly: Follow the recommended escalation schedule. Rushing leads to worse nausea
- Eat smaller meals: Large meals on a suppressed stomach are the #1 trigger for nausea
- Stay hydrated: Especially important given the risk of diarrhea and reduced food intake
- Avoid greasy foods: High-fat meals are harder to digest with slowed gastric emptying
- Time your injection: Some people find injecting before bed reduces daytime nausea
For complete side effect information, see our guides on tirzepatide side effects and semaglutide side effects.
Cardiovascular Benefits: A Key Difference
This is one area where semaglutide currently has a clear advantage over tirzepatide: proven cardiovascular benefit.
The SELECT trial (NEJM, 2023) demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in over 17,000 patients with overweight/obesity and established cardiovascular disease, without diabetes. This was a landmark result that positioned semaglutide as the first obesity medication with proven heart protection.
Tirzepatide does not yet have equivalent cardiovascular outcome data. The SURPASS-CVOT trial is underway but results have not been published. Early signals from metabolic improvements (blood pressure, lipids, inflammation markers) are encouraging, but until a dedicated outcomes trial confirms cardiovascular benefit, this remains an unanswered question.
What This Means Practically
If cardiovascular risk reduction is a priority (especially for someone with existing heart disease), semaglutide has the stronger evidence base right now. For someone primarily focused on weight loss without specific cardiovascular concerns, tirzepatide's superior efficacy data may be more relevant. As a 2025 expert review in Expert Opinion on Pharmacotherapy summarized: "Semaglutide offers robust cardiovascular protection; tirzepatide yields greater weight loss and broad metabolic benefits."
Tirzepatide vs Semaglutide Cost
Cost is a significant factor for most people choosing between these medications. Prices vary widely depending on the formulation (brand-name autoinjectors vs compounded vials) and insurance coverage.
Brand-Name Pricing (US, Without Insurance)
| Product | Indication | Approx. Monthly Cost |
|---|---|---|
| Mounjaro (tirzepatide) | Type 2 Diabetes | $1,000–$1,200 |
| Zepbound (tirzepatide) | Obesity | $1,000–$1,200 |
| Ozempic (semaglutide) | Type 2 Diabetes | $900–$1,000 |
| Wegovy (semaglutide) | Obesity | $1,300–$1,400 |
Compounded Formulations
Compounded tirzepatide and semaglutide from 503B-registered pharmacies typically cost $200–$500 per month, depending on dose and supplier. This has made both compounds accessible to a much wider population. Compounded versions use the same active peptide but are supplied as lyophilized powder requiring reconstitution, rather than pre-filled autoinjectors.
Insurance coverage remains inconsistent for both medications, particularly for the obesity indications. Many plans cover Mounjaro and Ozempic for type 2 diabetes but deny Zepbound and Wegovy for weight management.
Availability and Supply (2026 Update)
Supply conditions for both medications have shifted significantly since 2023. Here's the current landscape:
Brand-Name Availability
- Mounjaro/Zepbound (tirzepatide): Eli Lilly has expanded manufacturing capacity. Supply has stabilized in most US markets, though some dose strengths still see intermittent shortages
- Ozempic/Wegovy (semaglutide): Novo Nordisk ramped production through 2024-2025. Wegovy remains harder to find than Ozempic in some regions
- Rybelsus (oral semaglutide): Generally available; less demand pressure than injectables
Compounded Availability
Both tirzepatide and semaglutide remain available through 503B-registered compounding pharmacies. The FDA's evolving stance on compounded GLP-1 medications is an ongoing consideration. Check current regulations before sourcing. Compounded formulations are typically supplied as lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water.
For reconstitution guidance, see our peptide reconstitution guide.
Visualize Your Compound Levels
Our pharmacokinetic calculators show exactly what happens in your body between doses: peak levels, trough levels, and time to steady state.
Which Is Right for You: Tirzepatide or Semaglutide?
Neither is universally "better." The right choice depends on your priorities, medical history, and practical circumstances.
Tirzepatide May Be a Better Fit If:
- Maximum weight loss is your primary goal, and tirzepatide consistently produces greater reductions in clinical data
- You have type 2 diabetes and want superior blood sugar control (SURPASS-2 showed clear superiority over semaglutide)
- You've tried semaglutide and plateaued, and the dual-agonist mechanism may produce additional response
- You respond well to lower doses, and tirzepatide 5mg matches semaglutide 2.4mg for weight loss
Semaglutide May Be a Better Fit If:
- Cardiovascular protection is important, as the SELECT trial provides strong evidence for heart benefit
- You prefer an oral option: oral semaglutide exists (the Ozempic pill for diabetes, which reformulated and renamed Rybelsus in 2026, and the Wegovy pill for weight); no oral tirzepatide is available
- You want a longer track record, as semaglutide has been on the market since 2017 with more long-term safety data
- Insurance or cost favors it, so check your specific plan coverage for both options
- You prefer more stable blood levels, as semaglutide's longer half-life (~7 days vs ~5 days) means less fluctuation between doses
Switching Between Tirzepatide and Semaglutide
Switching from one to the other is common. There's no established dose-equivalence table, so the standard approach is:
- Allow your current medication to wash out (1-2 weeks after last dose)
- Start the new medication at its lowest dose regardless of your previous dose
- Titrate up on the standard schedule and don't skip steps
- Expect some adjustment period as the receptor activity profile changes
The Bottom Line: Tirzepatide vs Semaglutide
Verdict
For weight loss, tirzepatide wins. The data is consistent across trials: tirzepatide 15mg produces ~6 percentage points more weight loss than semaglutide 2.4mg, and even tirzepatide's lowest dose (5mg) matches semaglutide's 2.4mg result. The dual GIP/GLP-1 mechanism delivers meaningfully stronger results.
For cardiovascular protection, semaglutide wins. The SELECT trial is the only large-scale cardiovascular outcomes trial completed for either drug in an obesity population. Until tirzepatide's SURPASS-CVOT data is published, semaglutide has the stronger evidence for heart health.
For cost, it's a draw. Brand-name pricing is comparable. Compounded pricing is comparable. Insurance coverage is equally inconsistent for both.
For most people focused primarily on weight loss (which is the majority of the GLP-1 user population), tirzepatide is the stronger option based on current evidence. If you have established cardiovascular disease or high cardiac risk, semaglutide's proven heart benefit may tip the balance. Either way, both are highly effective medications with robust clinical data.
Ready to Start? Model Your Dosing
See projected drug levels, plan titration steps, and compare timelines with our free calculators.
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
Clinical trial data consistently shows tirzepatide produces greater weight loss than semaglutide. In the head-to-head SURPASS-2 trial, tirzepatide 15mg led to 5.5 kg more weight loss than semaglutide 1mg. In separate obesity trials, tirzepatide 15mg achieved 20.9% body weight reduction (SURMOUNT-1) compared to semaglutide 2.4mg's 14.9% (STEP 1). However, individual responses vary, and "better" depends on your full health picture.
What is the difference between tirzepatide and semaglutide?
The main difference is receptor targeting. Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors (dual agonist). This dual mechanism gives tirzepatide enhanced effects on insulin sensitivity and fat metabolism. Other differences include half-life (tirzepatide ~5 days, semaglutide ~7 days), dosing ranges, and available formulations. Semaglutide has oral versions (the Ozempic pill 1.5/4/9mg for type 2 diabetes, which reformulated and renamed Rybelsus in 2026, and the Wegovy pill 25mg for weight management) while tirzepatide is injection-only.
Can you switch from semaglutide to tirzepatide?
Yes, switching from semaglutide to tirzepatide is common. The recommended approach is to allow a washout period of 1-2 weeks after your last semaglutide dose, then start tirzepatide at the lowest dose (2.5mg) and titrate up on the standard 4-week schedule. Do not attempt to start at a "comparable" high dose. The medications have different receptor profiles and your body needs time to adjust.
Is Mounjaro the same as Ozempic?
No. Mounjaro contains tirzepatide (a dual GIP/GLP-1 agonist by Eli Lilly) and Ozempic contains semaglutide (a GLP-1 agonist by Novo Nordisk). They are different molecules with different mechanisms of action, different dosing schedules, and different clinical trial data. Both are FDA-approved for type 2 diabetes and both produce significant weight loss, but they are not interchangeable.
How much weight can you lose on tirzepatide vs semaglutide?
In clinical trials, tirzepatide 15mg produced average weight loss of 20.9% of body weight over 72 weeks (SURMOUNT-1), while semaglutide 2.4mg produced 14.9% over 68 weeks (STEP 1). For a 220-pound person, that translates to roughly 46 lbs on tirzepatide vs 33 lbs on semaglutide. Individual results vary significantly, and factors like starting weight, diet, exercise, and genetics all influence outcomes.
Does tirzepatide work if semaglutide didn't?
It's possible. Because tirzepatide works through an additional receptor (GIP) that semaglutide doesn't target, some people who respond poorly to semaglutide may respond to tirzepatide's dual mechanism. However, this hasn't been specifically studied in a clinical trial of semaglutide non-responders, so there's no guarantee. If you've plateaued on semaglutide, switching to tirzepatide is a reasonable option to discuss.
What are the side effects of tirzepatide vs semaglutide?
Both medications share similar gastrointestinal side effects: nausea, diarrhea, vomiting, and decreased appetite. In the SURPASS-2 head-to-head trial, rates were comparable. Nausea affected 17-22% on tirzepatide vs 18% on semaglutide. Most side effects are mild to moderate, occur during dose escalation, and improve over time. See our detailed guides on tirzepatide side effects and semaglutide side effects.
Is tirzepatide or semaglutide better for type 2 diabetes?
The SURPASS-2 trial directly compared the two for type 2 diabetes and found tirzepatide superior at all dose levels. Tirzepatide 15mg reduced HbA1c by 2.30% vs semaglutide 1mg's 1.86% reduction. However, semaglutide has proven cardiovascular benefits (SELECT trial) which are important for many diabetes patients. Both are excellent options, and the choice may depend on your specific cardiovascular risk profile.
How much does tirzepatide cost compared to semaglutide?
Brand-name pricing is similar: Mounjaro/Zepbound (tirzepatide) costs roughly $1,000-$1,200/month and Ozempic/Wegovy (semaglutide) costs $900-$1,400/month without insurance. Compounded formulations of both are significantly cheaper, typically $200-$500/month. Insurance coverage varies widely; diabetes indications are generally better covered than obesity indications for both medications.
Are tirzepatide and semaglutide both FDA-approved?
Yes. Both are FDA-approved for type 2 diabetes and chronic weight management. Tirzepatide is approved as Mounjaro (diabetes, May 2022) and Zepbound (obesity, November 2023). Semaglutide is approved as Ozempic (diabetes, December 2017), Wegovy (obesity, June 2021), and, in oral form, the Ozempic pill (diabetes, 2026, which reformulated and renamed Rybelsus) and the Wegovy pill (weight, December 2025). Semaglutide has been on the market longer and has more post-marketing safety data.
Plan Your GLP-1 Dosing Schedule
Use our free pharmacokinetic calculators to visualize drug levels, plan your titration, and track biometrics over time.
References
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
- Mondoh A, Crotty M, le Roux CW. Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape. Expert Opin Pharmacother. 2025;26(17):1841-1854. PubMed
- Shil KK, Hira AD, Bakchi S, et al. Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison. Cureus. 2025;17(12):e98858. PubMed
- Neves JS, Leite AR, Vale C, et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of SURPASS-2. Diabetologia. 2025. PubMed
- FDA. Mounjaro (tirzepatide) Prescribing Information. FDA.gov
- FDA. Wegovy (semaglutide) Prescribing Information. FDA.gov
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. It does not replace professional guidance from a qualified healthcare provider. Always consult your doctor before starting, changing, or stopping any medication. Individual results vary based on health status, genetics, lifestyle, and other factors. Neither tirzepatide nor semaglutide should be used without appropriate medical supervision.
Related Articles
Tirzepatide Complete Hub
Everything about Mounjaro & Zepbound: mechanism, trials, dosing, calculators.
Semaglutide Complete Hub
Everything about Ozempic & Wegovy: mechanism, dosing, calculators.
Tirzepatide Dosing Guide
Detailed titration schedules and protocols for tirzepatide.
Semaglutide Dosing Guide
Complete dosing protocols for Ozempic and Wegovy schedules.
Tirzepatide Side Effects
What to expect and how to manage common side effects.
Semaglutide Side Effects
Side effect rates, timelines, and management strategies.
Ozempic vs Wegovy
Same semaglutide, different doses and indications explained.
Retatrutide vs Tirzepatide
Triple agonist vs dual agonist: the next generation comparison.
Understanding Pharmacokinetics
Half-life, steady state, and drug level science explained.